Effect of intraperitoneally, intravenously and intralesionally administered monoclonal anti-β-FGF antibodies on rat chondrosarcoma tumour vascularization and growth

Anticancer Research

Volumn 17, Issue 3 C, 1997, Pages 2033-2039

  Coppola, Germano ^a   Atlas White, Maria ^d   Katsahambas, Sivi ^d   Bertolini, Joseph ^a   Hearn, Milton T W ^b   Underwood, John R ^c  

^a Commonwealth Serum Laboratory ^*  (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d NONE

Author keywords

Fibroblast growth factor; Monoclonal antibodies; Rat chondrosarcoma

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; MONOCLONAL ANTIBODY; TECHNETIUM 99M;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CATTLE; CELL CULTURE; CHONDROSARCOMA; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENDOTHELIUM CELL; ERYTHROCYTE; IMMUNOTHERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR GROWTH; TUMOR VASCULARIZATION;

3T3 CELLS; ANIMALS; ANTIBODIES, MONOCLONAL; AORTA; CATTLE; CELL DIVISION; CELLS, CULTURED; CHONDROSARCOMA; ENDOTHELIUM, VASCULAR; FIBROBLAST GROWTH FACTOR 2; INJECTIONS, INTRAPERITONEAL; INJECTIONS, INTRAVENOUS; METABOLIC CLEARANCE RATE; MICE; NEOVASCULARIZATION, PATHOLOGIC; RATS; RATS, WISTAR; REGIONAL BLOOD FLOW; TECHNETIUM;

EID: 0030878799     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Gospodarowicz D, Neufeld G, and Schweigerer L: Fibroblast growth factor: structure and biological properties. J Cell Physiol Supplement 5: 15-26, 1987.
2. Kandel J, Bossy-Wetzel E, Radvanyl F, Klagsbrun M, Folkman J and Hanahan D: Neovascularization is associated with a switch to the export of U-FGF in the multistep development of fibrosarcoma. Cell 66: 1095-1104, 1991.
3. Yayon A and Klagsbrun M: Autocrine regulation of cell growth and transfommation by basic fibroblast growth factor. Cancer Metastasis Rev 9:191-202, 1990.
4. Baselga J and Mendelsohn J: Receptor blockage with monoclonal antibodies as anti-cancer therapy. Pharmacol Ther 64: 127-154, 1994.
5. Imanishi K, Yamaguchi K, Kuranami M, Kyo E, Hozumi T and Abe K: Inhibition of human lung adenocarcinoma cell lines by anti-transforming growth factor-α monoclonal antibody. J Natl Cancer Inst 81: 220-223, 1989.
6. Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamara T, Brem, H and Folkman J: Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348: 555-557, 1990.
7. Maione TE, Gray GS, Petro J, Hunt AJ, Donner AI, Bauer S, Carson HS and Sharp RJ: Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247: 77-79, 1990.
8. Taylor S and Folkman J: Protamine is an inhibitor of angiogenesis. Nature 297: 307-312, 1982.
9. Baird BA, Mormede P and Bohlen P: Immunoreactive fibroblast growth factor (FGF) in a transplantable chondrosarcoma: inhibition of tumour growth by antibodies to FGF. J Cell Biochem 30: 79-85: 1986.
10. Hori A, Sasada R, Matsutani E, Naito K, Sakura Y, Fujita T and Kozai Y: Suppression of solid tumour growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 57: 6180-6184, 1991.
11. Stan AC, Nemati MN, Pietsch T, Walter GP, and Dietz H: In vivo inhibition of angiogenesis and growth of the human U-87 malignant glial tumor by treatment with an antibody against basic fibroblast growth factor. J Neurosurg 82: 1044-1052, 1995.
12. Takahashi JA, Fukumoto M, Kozai Y, Ito N, Oda Y, Kikuchi H and Hatanaka M: Inhibition of cell growth and tumoungenesis of human glioblastoma eells by a neutralizing antibody against human basic fibroblast growth factor. FEBS Lett 288: 65-71, 1991.
13. Dennis PA and Rifkin DB: Studies on the role of basic fibroblast growth factor in vivo: inability of neutralizing antibodies to block tumour growth. J Cell Physiol 144: 84-98, 1990.
14. Matsuzaki K, Yoshitake Y, Matuo Y, Sasaki H and Mshikawa K: Monoclonal antibodies against heparin-binding growth factor II/basic fibroblast growth factor that bloek its biological activity: invalidity of the antibodies for tumour angiogenesis. Proc Natl Acad Sci U.S.A. 56:9911-9915, 1989.
15. Reilly TM, Taylor DS, Herblin WS, Thoolen MJ, Chium AT, Watson DW and Timmermans WM: Monoclonal antibodies directed against basic fibroblast growth factor which inhibit its biological activity in vitro and in vivo. Biochem Biophys Res Commun 164: 736-743, 1989.
16. Guthridge M, Bertolini J, Schmitt J and Heam MTW: Detection of FGF-B mRNA in chondrosarcoma cells by a new in situ hybridization technique with synthetic oligonucleotide probes. J Biochem Biophys Meth 22: 279-288, 1991.
17. Choi HU, Meyer K, and Swarm R: Mucopolysaccharide and protein-polysaccharide of a transplantable rat chondrosarcoma. Proc Natl Acad Sci 68: 877-879, 1971.
18. Neufeld G, Mitchell R, Ponte P and Gospodarowicz D: Expression of human basic fibroblast growth factor cDNA in baby hamster kidney-derived cells results in autonomous cell growth. J Cell Biol 106: 1385-1394, 1988.
19. Rogelj S, Weinberg RA, Fanning P and Klagsbrun M: Characterization of tumours produced by signal peptide-basic fibroblast growth factor-transformed cells. J Cell Biochem 39: 13-23, 1989.
20. Shulze-Osthoff K, Risau W, Volimer E and Song C: In situ detection of basic fibroblast growth factor by highly specific antibodies. Am J Pathol 137: 85-92, 1990.
21. Jain RK AND Baxter LT: Mechanism of heterogenous distribution of monoclonal antibodies and other macromolecules in tumours: significance of elevated interstitial pressure. Cancer Res 48: 7022-7032, 1988.
22. Solesvik OV, Rofstad EK and Brustad T: Vascular structure of five human malignant melanomas grown in athymic nude mice. Br J Cancer 46: 557-567, 1982.
23. Vaupel P, Kallinowski F and Okunieff P: Blood flow, oxygen and nutrient supply, and metabolic microenviroment of human tumours: A review. Cancer Res 49: 6449-6465, 1989.
24. Jain RK: Transport of molecules in the tumour interstitium: a review. Cancer Res 47: 3039-3052, 1987
25. Chatenoud L: The immune response against therapeutic monoclonal antibodies. Immunol. Today 7: 367-368, 1986.
26. Shawler DL, Bartholomew RM, Smith LM and Dillman RO: Human immune response to multiple injections of murine monoclonal IgG. J Immunol 135: 1530-1535, 1985.
27. Zuckier LS, Rodrigues LD, Schaffl MD: Immunological and pharmacological concepts of monoclonal antibodies. Semin Nucl Med 65: 166-186, 1989.
28. Jain RK: Determinants of tumour blood flow: a review. Cancer Res 48: 2641-2658, 1988.
29. Jain RK: Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumours. Cancer Res 50: 814-819, 1990.
30. Nugent LJ AND Jain RK. Extravascular diffusion in normal and neoplastic tissues. Cancer Res 44: 238-244, 1984.
31. Tozer GM, Lewis S, Michalowski A, Aber V: The relationship between regional variations in blood flow and histology in a transplantable rat fibrosarcoma. Br J Cancer 61: 250-257, 1990.
32. Epenetos AA, Nimon CC, Arklie J, Elliott TA, Hawkins WR, Britton KE and Bodmer FW: Detection of human cancer in an animal model using radio-labelled tumour- associated monoclonal antibodies. Br J Cancer 46: 1-8, 1982.
33. Griffin TW, Collins G, Bokhari F, Stochi M, Bertran Brill A, Ito T, Edmond G and Sands H: Intraperitoneal immunoconjugates. Cancer Res 50: 1031-1038, 1990.
34. Saga T, Neumann RD, Heya T, Sato J, Kinuya S, Le N, Paik CH and Weinstein-JN: Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci U.S.A. 92: 8999-9003, 1995.
35. Andrew SM, Pimm MV, Perkins AE and Baldwin RW: Comparative imaging and biodistribution studies with anti-CEA monoclonal antibody and its F(ab')2 and Fab fragments in mice with colon carcinoma xenographs. Eur J Nucl Med 12: 169-75, 1986.
36. Colcher D, Bird R, Roselli M, Hardman K, Johnson S, Pope S, Dodd, SW, Pantoliano, MW, Milenic DE and Schlom J: In vivo tumour targeting of a recombinant single-chain antigen-binding protein. J Natl Cancer Inst 82: 1191-1197, 1990.
37. Lobuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J and Khazaeli MB: Mouse/human chimeric monoclonal antibodies in man: kinetics and immune response. Proc Natl Acad Sci U.S.A. 86: 4220-4224, 1989.
38. Wahl RL, Parker CW and Philpott GW: Improved radioimaging and tumour localization with monoclonal F(ab')2. J Nucl Med 24: 316-325, 1982.